Article
Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4.
Annals of hepatology - 1 Jan 2000
Urquijo Juan José, Diago Moisés, Boadas Jaume, Planas Ramón, Solá Ricard, Del Olmo Juan Angel, Crespo Javier, Erdozaín José Carlos, Antón María Dolores, Arocena Carlos, Suarez Dolores, Giné Josep, Barrera Josep M, Gracia-Samaniego Javier, Perez Ricardo, Dalmau Blai, Montoro Miguel
Abstract excerpt
The hepatitis C virus (HCV) genotype is an important predictive outcome parameter for pegylated interferon plus ribavirin therapy. Most published therapeutic trials to date have enrolled mainly patients with HCV genotypes 1, 2 and 3. Limited studies have focused on genotype 4 patients, who have had a poor representation in pivotal trials. Our aim was to evaluate the efficacy and safety of treatment with standard...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.